류마티스양 관절염에서 CD20dim T 세포의 발현

Abstract

Objective : This study was designed to investigate CD20dim expression on T cells between healthy control subjects and rheumatoid arthritis patients and to investigate the association between CD20dim T cells and clinical manifestations in rheumatoid arthriris.

Methods : Peripheral bloods from twenty seven healthy controls and twenty six rheumatoid patients were evaluated by dual color immunophenotyping. We used IgG1a and IgG2a for negative control, then divided T cells and B cells on Cd3/CD19 combination. And we evaluated two subpopulation CD5+CD20did T cell (CD20dim T cell) and CD5+CD20bright cell (CD5 B cell) on CD5/20 combination for comparison. In order to correlate the CD20dim T cell data with patient's clinical status, patients characteristics such as age, disease duration, morning stiffness, rheumatoid factor (RF), and antinuclear antibody (ANA) were reviewed.

Results : The mean percent positivity of T cells (CD3) and B cells (CD19) in 27 healthy control donors was 63.2±7.7%, and 11.4%±2.6%. The mean percentages of CD20dim T cell and CD5 B cell (Leul) were 2.3±1.0% and 1.4±0.9% and upper limit of reference values of CD20dim T cells and CD5 B cells (Leul) that calculated from normal healthy controls were 4.3% and 3.2%. Compared with healthy controls, CD20dim T cells were significantly elevated in total patient groups (4.4±2.7%, p<0.01). and significantly increased more than upper limit of reference values in eleven of 26 patients. Compared with CD20dim T cells according to disease duration, disease duration of most patients (10/11) with elevated CD20dim T cell were less than 2 years.

Conclusion : The results indicated that CD20dim T cells were expressed at low levels in healthy controls but elevated levels of CD20dim T cells in rheumatoid arthritis patients were observed and close relationship to CD20dim T cells expression and disease duration was noted.